학술논문
Serum-Associated Antibiotic Tolerance in Pediatric Clinical Isolates of Pseudomonas aeruginosa.
Document Type
Article
Author
Source
Subject
*BLOOD serum analysis
*ANTIBIOTICS
*HOSPITAL care of children
*COMPARATIVE studies
*CYSTIC fibrosis
*CLINICAL pathology
*DRUG resistance in microorganisms
*DRUG tolerance
*INTRAVENOUS therapy
*MICROBIAL sensitivity tests
*PSEUDOMONAS
*SPUTUM
*TOBRAMYCIN
*TRACHEAL diseases
*TRACHEOTOMY
*PHENOTYPES
*DISEASE prevalence
*CONTRAST media
*MINOCYCLINE
*IN vitro studies
*COLONY-forming units assay
*PHARMACODYNAMICS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2048-7193
Abstract
Background When grown in human serum, laboratory isolates of Pseudomonas aeruginosa exhibit tolerance to antibiotics at inhibitory concentrations. This phenomenon, known as serum-associated antibiotic tolerance (SAT), could lead to clinical treatment failure of pseudomonal infections. Our purpose in this study was to determine the prevalence and clinical impact of SAT in Pseudomonas isolates in hospitalized children. Methods The SAT phenotype was assessed in patients aged <18 years admitted with respiratory or blood cultures positive for P. aeruginosa. The SAT phenotype was a priori defined as a ≥2-log increase in colony-forming units when grown in human serum compared with Luria-Bertani medium in the presence of minocycline or tobramycin. Results SAT was detected in 29 (64%) patients. Fourteen patients each (34%) had cystic fibrosis (CF) and tracheostomies. Patient demographics and comorbidities did not differ by SAT status. Among CF patients, SAT was associated with longer duration of intravenous antibiotics (10 days vs 5 days; P < .01). Conclusions This study establishes that SAT exists in P. aeruginosa from human serum and may be a novel factor that contributes to differences in clinical outcomes. Future research should investigate the mechanisms that contribute to SAT in order to identify novel targets for adjunctive antimicrobial therapies. [ABSTRACT FROM AUTHOR]